Celyad Oncology reports 47,261,905 issued shares, 74,883,166 voting rights

• Celyad Oncology lifted issued share capital to EUR 10.44 million on July 16, 2026, issuing 2,500,000 new shares to a Fortress affiliate.
• Total issued shares rose to 47,261,905, split between 19,640,644 single-vote shares, 27,621,261 double-vote shares.
• Total voting rights increased to 74,883,166.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celyad Oncology SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722466989) on July 22, 2026, and is solely responsible for the information contained therein.